Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Amicus Therapeutics Inc shares valued at $1,074,750 were purchased by BRADLEY CAMPBELL on Jan 20 ’26. At $14.33 per share, BRADLEY CAMPBELL acquired 75,000 shares.
Also, Clark David Michael sold 25,642 shares, netting a total of over 363,380 in proceeds. Following the sale of shares at $14.17 each, the insider now holds 245,690 shares.
Before that, DAVID CLARK had added 25,642 shares to its account. In a trade valued at $279,241, the Officer bought Amicus Therapeutics Inc shares for $10.89 each.
As published in a research note from Leerink Partners on December 29, 2025, Amicus Therapeutics Inc [FOLD] has been rated down from an Outperform to a Market perform and the price target has been revised to $14.50. Analysts at TD Cowen downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in late December. As of December 17, 2025, Citigroup has initiated its “Buy” rating for FOLD. Earlier on September 18, 2025, Needham upgraded its rating. Their new recommendation was “a Buy” for FOLD stock which previously was a “a Hold”.
Analyzing FOLD Stock Performance
On last trading session, Amicus Therapeutics Inc [NASDAQ: FOLD] rose 0.28% to $14.35. The stock’s lowest price that day was $14.305, but it reached a high of $14.36 in the same session. During the last five days, there has been a surge of approximately 0.21%. Over the course of the year, Amicus Therapeutics Inc shares have jumped approximately 52.50%.
Is Amicus Therapeutics Inc subject to short interest?
Stocks of Amicus Therapeutics Inc saw a sharp steep in short interest on 2025-12-31 dropping by -0.25 million shares to 19.06 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 19.31 million shares. A decline of -1.31% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 1.18 of the overall float, the days-to-cover ratio (short ratio) decline to 1.18.
Which companies own the most shares of Amicus Therapeutics Inc (FOLD)?
In terms of Amicus Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 14.25 in the next 12 months, down nearly -0.42% from the previous closing price of $14.31. Analysts anticipate Amicus Therapeutics Inc stock to reach 14.5 by 2026, with the lowest price target being 14. In spite of this, 5 analysts ranked Amicus Therapeutics Inc stock as Buy at the end of 2026. On July 17, 2025, Morgan Stanley assigned a price target of “an Overweight” to the stock and upgraded coverage with a $108.
